Rituximab treatment in a child with rosai-dorfman disease and systemic lupus erythematosus.
Alqanatish
Jubran Theeb
JT
Houghton
Kristin
K
Bond
Mason
M
Senger
Christof
C
Tucker
Lori B
LB
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D015618:Histiocytosis, Sinus / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013902:Radiography, Thoracic; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone